Compare MC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | ICUI |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 3.2B |
| IPO Year | 2014 | 1992 |
| Metric | MC | ICUI |
|---|---|---|
| Price | $70.22 | $146.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $73.75 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 863.8K | 236.5K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ 446.16 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | $1,467,580,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $21.89 | ★ N/A |
| Revenue Growth | ★ 51.19 | N/A |
| 52 Week Low | $47.00 | $107.00 |
| 52 Week High | $82.89 | $175.51 |
| Indicator | MC | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 60.02 |
| Support Level | $68.37 | $145.32 |
| Resistance Level | $72.26 | $148.95 |
| Average True Range (ATR) | 2.28 | 3.86 |
| MACD | 0.44 | -0.55 |
| Stochastic Oscillator | 79.94 | 65.31 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.